TRAJANTA DUO 2.5/850 10 S

About

TRAJANTA DUO 2.5/850 is a fixed-dose combination medication containing Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Metformin hydrochloride, a biguanide. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Linagliptin works by increasing incretin hormone levels, which enhances glucose-dependent insulin secretion and reduces glucagon secretion. Metformin primarily reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues. This dual mechanism of action provides comprehensive glycemic control by addressing multiple pathophysiological defects in type 2 diabetes, helping patients achieve target blood sugar levels when diet and exercise alone are insufficient.

Uses

• Management of type 2 diabetes mellitus.
• As an adjunct to diet and exercise.
• When monotherapy with Metformin is insufficient.
• In combination with other antidiabetic agents.

Directions For Use

Take orally, usually twice daily with meals, as prescribed by your healthcare provider.

Benefits

• Provides comprehensive glycemic control.
• Effectively reduces HbA1c levels.
• Low risk of hypoglycemia when used alone.
• Generally weight-neutral.
• Convenient fixed-dose combination.
• Improves both fasting and post-meal glucose.

Side Effects

• Nasopharyngitis
• Diarrhea
• Nausea
• Vomiting
• Abdominal pain
• Headache
• Dizziness
• Cough
• Rash
• Pancreatitis (rare)
• Lactic acidosis (rare)
• Hypoglycemia (especially with other agents)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption due to the increased risk of lactic acidosis, a rare but serious side effect associated with Metformin.
• Pregnancy - Consult your doctor before use. This medication is generally not recommended during pregnancy unless the potential benefits outweigh the risks to the fetus.
• Breastfeeding - Not recommended during breastfeeding as Metformin is excreted in breast milk and the effects of Linagliptin on infants are unknown.
• Liver - Contraindicated in severe hepatic impairment due to the Metformin component, which increases the risk of lactic acidosis.
• Kidney - Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73 m²). Dose adjustment is required for moderate impairment.
• Lung - Use with caution in severe respiratory conditions that may lead to hypoxia, as this can increase the risk of lactic acidosis with Metformin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.